Psilocybin therapy

Phase 2Small molecule

UUniversity of California, San Francisco

Psilocybin therapy is one of 30 small molecule programs targeting Bipolar II Disorder. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bipolar II DisorderActive, not recruiting

Alcohol Use DisorderCompleted

Adjustment DisorderRecruiting

PsilocybinNot yet recruiting

Bipolar II DisorderPhase 2

Active, not recruiting

Alcohol Use DisorderPreclinical

Completed

Adjustment DisorderPhase 2

Recruiting

PsilocybinPhase 2

Not yet recruiting

Competition

Competitive Landscape

25 competitors in Alcohol Use Disorder

#DrugCompanyPhaseTrials

Revia

Teva

Approved

6 2

Antabuse

Teva

Approved

2 3

Ozempic

Novo Nordisk

Phase 3

4 4

Psilocybin

COMPASS Pathways

Phase 3

8 5

Otezla

Amgen

Phase 2

3 6

Aldactone

Pfizer

Phase 2

2 7

Mounjaro

Eli Lilly

Phase 2

1 8

Ketalar

AAultman Health Foundation

Phase 2

6 9

Naltrexone Pill

YYale University

Phase 3

2 10

Chantix

PPrism Pharmaceuticals

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Adjustment Disorder

NCT07072728

Q1 2028

Phase 2Not yet recruiting

Psilocybin

NCT06782724

Clinical

Trials by Indication[1]

Psilocybin1 trial

Psilocybin Therapy for Psychological Distress in Palliative Patients

Not yet recruiting·UUniversity Medical Center Groningen·Phase 2·NCT06782724·108 enrolled

Alcohol Use Disorder1 trial

Psilocybin in Alcohol Use Disorder With Comorbid Depression

Completed·—·N/A·NCT06235411·30 enrolled

Bipolar II Disorder1 trial

Psilocybin Therapy for Depression in Bipolar II Disorder

Active, not recruiting·UUniversity of California, San Francisco·Phase 2·NCT05065294·14 enrolled

Adjustment Disorder1 trial

A Phase 2b Double-blind, Randomized, Low-dose Comparator-controlled Clinical Trial to Assess the Efficacy and Safety of NPX-5 in Psilocybin-assisted Psychotherapy for the Treatment of Adjustment Disorder Associated With Cancer.

Recruiting·PPsyence Australia Pty Ltd·Phase 2·NCT07072728·87 enrolled

Parkinson disease1 trial

Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease: a Pilot Study

Completed·JJoshua Woolley, MD, PhD·Phase 2·NCT04932434·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Psilocybin therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Psilocybin therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Psilocybin therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of California, San Francisco company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of California, San Francisco

Psilocybin therapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q1 2028

Trials by Indication[1]

Psilocybin1 trial

Alcohol Use Disorder1 trial

Bipolar II Disorder1 trial

Adjustment Disorder1 trial

Parkinson disease1 trial

References

Drug Info

Quick Facts

Related News